Cite
APA Citation
Chi, K. N., Taavitsainen, S., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G., Tran, B., Azad, A., Wood, L., Gingerich, J. R., North, S., Pezaro, C. V., Ruether, D., Sridhar, S. S., Annala, M., Bacon, J., & Wyatt, A. W. (n.d.). 792OA randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095508852.0x000032